BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34713830)

  • 1. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
    Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
    Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
    Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
    Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
    Montero AJ; Eapen S; Gorin B; Adler P
    Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic burden of end-of-life care in metastatic breast cancer.
    Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
    J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
    Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
    Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
    Lin YJ; Kuo CN; Ko Y
    Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
    Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
    J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US.
    Kong AM; Pavilack M; Huo H; Shenolikar R; Moynihan M; Marchlewicz EH; Chebili-Larson C; Min S; Subramaniam DS
    J Med Econ; 2021; 24(1):328-338. PubMed ID: 33576296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect costs associated with metastatic breast cancer.
    Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
    J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
    Abraham P; Kish JK; Korytowsky B; Radtchenko J; Singh P; Shaw J; Feinberg B
    J Med Econ; 2020 Feb; 23(2):125-131. PubMed ID: 31581922
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 19. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
    Trogdon JG; Baggett CD; Gogate A; Reeder-Hayes KE; Rotter J; Zhou X; Ekwueme DU; Fairley TL; Wheeler SB
    Breast Cancer Res Treat; 2020 Jun; 181(3):653-665. PubMed ID: 32346820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.